1.
Article
in English
| IMSEAR
| ID: sea-90428
ABSTRACT
AIMS: Moxonidine, a new imidazoline II receptor agonist was evaluated in patients with essential hypertension. METHODOLOGY: After an informed consent, 16 patients with essential hypertension were recruited. After a wash out period, the patients received increasing doses of Moxonidine (maximum dose 0.6 mg) for four weeks to control the blood pressure. RESULTS: The mean reduction in blood pressure (systolic/diastolic) was 17.6/14.5 mm Hg in supine position and 18.2/12.6 mm Hg in standing position. The significant side effect was observed only in one patient. CONCLUSIONS: Moxonidine thus appears to be safe and effective antihypertensive drug in patients with essential hypertension.
Subject(s)
Adult , Aged , Antihypertensive Agents/adverse effects , Blood Pressure/drug effects , Epistaxis/chemically induced , Female , Humans , Hypertension/drug therapy , Imidazoles/adverse effects , Male , Middle Aged , Severity of Illness Index
2.
Article
in English
| IMSEAR
| ID: sea-93027